A month after Sutro closed an $85.4m series E round, the cancer drug developer, based on research at Stanford, has filed for a $75m initial public offering.
Sutro Biopharma, a US-based cancer drug developer backed by pharmaceutical firms Amgen, Celgene, Eli Lilly and Merck & Co that is based on research at Stanford University, filed for a $75m initial public offering on the Nasdaq Global Market on Wednesday.
Founded in 2003 as Fundamental Applied Biology, Sutro Biopharma is creating immuno-onology treatments, antibody drug conjugates and bispecific antibodies aimed at cancer and autoimmune diseases.
The company’s drug discovery platform, XpressCF, is based on research by founder James…
